KemPharm, Inc. (NASDAQ:KMPH) Given a $13.00 Price Target at Oppenheimer Holdings, Inc.
KemPharm, Inc. (NASDAQ:KMPH) has been assigned a $13.00 price objective by analysts at Oppenheimer Holdings, Inc. in a research report issued on Thursday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price objective indicates a potential upside of 333.33% from the company’s previous close.
A number of other analysts have also issued reports on KMPH. Royal Bank Of Canada set a $8.00 target price on shares of KemPharm and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Zacks Investment Research lowered shares of KemPharm from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Roth Capital initiated coverage on shares of KemPharm in a research report on Wednesday, June 28th. They set a “buy” rating and a $8.00 target price on the stock. ValuEngine upgraded shares of KemPharm from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 1st. Finally, Canaccord Genuity set a $7.00 target price on shares of KemPharm and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $8.10.
KemPharm (NASDAQ KMPH) opened at 3.00 on Thursday. KemPharm has a one year low of $2.90 and a one year high of $5.50. The stock’s 50 day moving average price is $3.48 and its 200 day moving average price is $3.92. The firm’s market capitalization is $43.94 million.
KemPharm (NASDAQ:KMPH) last issued its quarterly earnings data on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.63) by $0.21. Analysts expect that KemPharm will post ($2.80) EPS for the current year.
In other news, CEO Travis C. Mickle bought 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 20th. The shares were purchased at an average price of $3.45 per share, for a total transaction of $27,600.00. Following the completion of the transaction, the chief executive officer now owns 1,629,612 shares in the company, valued at $5,622,161.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have purchased 10,775 shares of company stock worth $38,783. 22.80% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in KMPH. C WorldWide Group Holding A S raised its stake in shares of KemPharm by 10.1% in the first quarter. C WorldWide Group Holding A S now owns 181,699 shares of the specialty pharmaceutical company’s stock worth $890,000 after buying an additional 16,699 shares during the period. Bank of New York Mellon Corp raised its stake in shares of KemPharm by 17.6% in the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 3,414 shares during the period. Finally, Victory Capital Management Inc. purchased a new stake in shares of KemPharm during the first quarter worth about $647,000. Hedge funds and other institutional investors own 42.27% of the company’s stock.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.